1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,090 | 23.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 09.01. | Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment | 253 | Business Wire | Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09.01. | SOTIO Biotech: SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target | 267 | Business Wire | SOT109 will leverage antibodies generated with Biocytogen's proprietary RenMab platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers SOTIO Biotech, a clinical-stage... ► Artikel lesen | |
| 08.01. | Biocytogen und Acepodia bündeln ihre Kräfte, um bispezifische Antikörper und Dual-Payload-ADCs zur Behandlung komplexer Tumore voranzutreiben | 271 | Business Wire | Zusammenarbeit initiiert Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Nutzlast (BsAD2Cs)
Biocytogens RenLite® trifft auf Acepodias AD2C für präzise onkologische... ► Artikel lesen | |
| 07.01. | Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors | 382 | Business Wire | Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs)
Biocytogen's RenLite® meets Acepodia's AD2C for precision oncology solutions
Biocytogen... ► Artikel lesen | |
| 06.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 2 | HKEx | ||
| 18.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass Adcendo ApS die Antikörperoption ausübt, um die ADC-Entwicklung zu beschleunigen | 371 | Business Wire | Adcendo übt seine Option aus, die vollständig humanen Antikörper von Biocytogen zu nutzen, um seine ADC-Pipeline für Krebserkrankungen mit hohem ungedecktem medizinischen Bedarf weiter auszubauen... ► Artikel lesen | |
| 16.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development | 268 | Business Wire | Adcendo exercises its option to utilize Biocytogen's fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need
This collaboration further validates... ► Artikel lesen | |
| 11.11.24 | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 2 | FierceBiotech | ||
| 11.11.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 376 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11.24 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| 25.09.24 | BIOCYTOGEN-B (02315): 2024 INTERIM REPORT | 1 | HKEx | ||
| 28.08.24 | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 31.07.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 327 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen | |
| 16.07.24 | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 323 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07.24 | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 327 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 21.06.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält US-Patent für seine gemeinsame Leichtketten-Mausplattform RenLite | 459 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab jetzt die Erteilung eines Patents durch das United States Patent and Trademark Office (USPTO) für die von Biocytogen... ► Artikel lesen | |
| 21.06.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform | 330 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLitefully human common... ► Artikel lesen | |
| 06.05.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt mit BioCopy eine Vereinbarung zur Evaluierung und potenziellen Lizenzierung von TCR-ähnlichen Antikörpern ab | 367 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das sich auf die Entdeckung neuartiger antikörperbasierter Therapeutika... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,665 | +0,45 % | PTA-News: Medigene AG: Medigene AG erweitert Patentportfolio um Patenterteilung für seine JOVI Technologie in den USA | DJ PTA-News: Medigene AG: Medigene AG erweitert Patentportfolio um Patenterteilung für seine JOVI Technologie in den USA
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/19.02.2025/11:00)... ► Artikel lesen | |
| BIOFRONTERA | 2,380 | -4,23 % | Top-Zock 2025: Formycon, Biofrontera oder BB Biotech? | Auf der Suche nach unserem Top-Zock 2025 haben wir unzählige Small- und Nano-Cap-Titel analysiert. Ein Wert sticht dabei mit einem überragenden Chance-Risiko-Profil über die nächsten Monate heraus.... ► Artikel lesen | |
| CLINUVEL | 6,865 | +0,66 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Investor Webinar | ||
| EDITAS MEDICINE | 1,841 | +0,55 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BLUEBIRD BIO | 3,820 | -2,55 % | Bluebird Bio wird von Carlyle und SK Capital Partners übernommen | ||
| ASEP MEDICAL | 0,048 | +0,42 % | ASEP Medical Holdings Inc: ASEP to issue 6.77 million shares for debt of $440,585 | ||
| CELLECTAR BIOSCIENCES | 0,310 | +1,31 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 4,470 | -1,54 % | Cardiff Oncology, Inc.: Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update | ||
| CLEAN HARBORS | 208,00 | -0,24 % | ROUNDUP: Clean Harbors Provides Q1, FY25 Adj. EBITDA Outlook | WASHINGTON (dpa-AFX) - While reporting its financial results for the fourth quarter on Wednesday, Clean Harbors Inc. (CLH, CLHB) initiated its adjusted EBITDA and adjusted free cash flow guidance... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,780 | -1,02 % | Spero Therapeutics Aktie: Stillstand oder stabiler Kurs? | Die Spero Therapeutics Aktie verzeichnet aktuell einen leichten Rückgang von 0,68 Prozent auf 0,831 USD (Stand: 22. Februar 2025). Mit einer Marktkapitalisierung von 42,5 Millionen Euro bewegt sich... ► Artikel lesen | |
| MESOBLAST | 1,560 | -3,11 % | Mesoblast Limited: Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings | NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,386 | +4,32 % | CStone Pharmaceuticals: Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting | CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,351 | +2,66 % | Chiesi Global, Protalix Announce EMA Validation Of Variation Submission For Pegunigalsidase Alfa | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chiesi Global Rare Diseases, a unit of Chiesi Group, and Protalix BioTherapeutics announced the European Medicines Agency has validated the Variation Submission... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 19,700 | -0,51 % | PALVELLA THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PURPLE BIOTECH | 3,400 | +3,34 % | Purple Biotech Ltd.: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial | NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+2,16 %) liegt der Kurs bei 0,945 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
